Acute Ischaemic StrokeNCT06379464
Screening of New Markers of Gut Microbiota in Stroke and Depression: a Cross-sectional Study
An observational study of Acute Ischaemic Stroke and Depression, run by Zhujiang Hospital at 1 site in China.
Trial summary
Objectives of Study: Through the cross-sectional study of stroke and depression, key biomarkers are targeted by screening disease-associated intestinal bacteria, metabolites and immune factors through multi-omics techniques. Read more about this study
- Who is it for?
- Ages 18 to 90 yearsHealthy volunteers can take part
- Conditions the study is for
- Acute Ischaemic Stroke, Depression
- How many people
- 320 participants
- Where
- 1 siteChina
- Study dates
- 1 Sep 2023to 30 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: 1. Patients with acute ischaemic stroke; 2. Depressed patients
Who may be able to join
- Age range from 18 to 90 years old;
- Patients who met the diagnostic criteria of the 2018 Chinese guidelines for the diagnosis and treatment of acute ischemic stroke;
- Sign the informed consent form, provide relevant medical history information and provide blood, urine and stool samples.
- Age range from 18 to 90 years old;
- Patients who met the depression related criteria in the Chinese classification and diagnostic criteria for mental disorders;
- Sign the informed consent form, provide relevant medical history information and provide oral swabs, blood, urine and stool samples.
Who cannot join
- Serious systemic diseases including malignancies;
- Alanine aminotransferase or aspartate aminotransferase >2 times the upper limit of normal value or severe liver disease;
- Creatinine >1.5 times the upper limit of normal or severe nephropathy;
- A long-term history of drinking, drug taking and chemical poisoning. A long-term history of drinking refers to a history of more than 5 years, equivalent to alcohol >40g/d for men and 20g/d for women, or a history of heavy drinking within 2 weeks, equivalent to alcohol >80g/d;
- Those with previous history of intestinal tumor, irritable bowel syndrome or inflammatory bowel disease or diagnosed in Hospital;
- Unable to retain the required samples.
Show all 13Show fewer
- Depressed patients:
- Serious systemic diseases including malignancies;
- Alanine aminotransferase or aspartate aminotransferase >2 times the upper limit of normal value or severe liver disease;
- Creatinine >1.5 times the upper limit of normal or severe nephropathy;
- A long-term history of drinking, drug taking and chemical poisoning. A long-term history of drinking refers to a history of more than 5 years, equivalent to alcohol >40g/d for men and 20g/d for women, or a history of heavy drinking within 2 weeks, equivalent to alcohol >80g/d;
- Those with previous history of intestinal tumor, irritable bowel syndrome or inflammatory bowel disease or diagnosed in Hospital;
- Unable to retain the required samples.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Zhujiang Hospital of Southern Medical University
Guanzhou, Guangdong, 510145
Hongwei Zhou, Professor, 186 8848 9622, hzhou@smu.edu.cn
About this study
Objectives of Study: Through the cross-sectional study of stroke and depression, key biomarkers are targeted by screening disease-associated intestinal bacteria, metabolites and immune factors through multi-omics techniques.
Read the detailed description
With environmental changes, population aging, and the accelerated pace of social life, cerebrovascular diseases and mental illnesses have gradually become a major disease burden in China. Stroke is the second leading cause of death globally, as well as the leading cause of death and disability in China. In recent years, the prevalence and incidence of stroke have increased significantly in our country. Global Burden of Disease 2017 reported a stroke incidence rate of 258 (95% CI, 234-284) per 100,000 person-years and a mortality rate of 88 (95% CI, 80-94) per 100,000 person-years. Depression is one of the most common psychiatric disorders, with a lifetime prevalence of 15-18%, a recurrence rate of approximately 80%, and a disease outcome that worsens with increasing age of onset. World Health Organization measurements show that the disease burden of depression accounts for 10% of the total burden of all types of illness and disability. Its pathogenesis is still unknown, treatment options are limited, and most patients suffer from recurrent or prolonged illness for life. The etiology and pathophysiological mechanisms of stroke and depression remain unknown, and objective and reliable biological diagnostic markers are lacking.
As research strategies focusing on the central nervous system have encountered difficulties, the field has begun to look to the periphery for new clues. With the advancement of multi-omics studies integrating genome, transcriptome, epigenome, proteome, and metabolomics, important roles of gut microbiota have been discovered to influence the function and structure of the nervous system by regulating metabolites, the immune system, and neurotransmitters, etc. Benakis et al. found that gut-derived IL17+γδ T cells migrate to the meninges and promote post-stroke injury. Clearance of gut microbiota induced changes in dendritic cell activity, increased Treg cells, and decreased IL17+γδ T cells, which in turn alleviated stroke injury. Therefore, T-lymphocytes dependent on intestinal immunity are strongly associated with stroke severity. Previous studies have shown that IL-17 produced by γδ T cells in the meninges is an important factor in inducing anxious behavior and IFN-γ is important in maintaining social willingness, whereas pro-inflammatory factors such as IL-1β, IL-6 and TNF-α produced by inflammatory responses are highly correlated with depression, so that T-cell immunity may be associated with depression. Stroke and depression present a similar pathogenesis and spectrum of disease traits. IL-17+γδ T cells have been shown to be involved in the mechanism of injury after ischemic stroke; high levels of IL-17 are associated with depression, which is a common comorbidity of diseases such as the above. This suggests that the relevant immune pathways represented by IL-17 and γδ T cells may be a common pathogenic mechanism for stroke and depression. Previous studies have also shown that both diseases exhibit enrichment of Enterobacteriaceae. The applicant's team's findings, published in Gut, reveal that ischemic stroke can trigger a disturbance of the gut microbiota characterized by an overproliferation of Enterobacteriaceae, and that the disturbed microbiota can further contribute to the progression of brain injury and is associated with poor stroke outcomes. The mechanism is that stroke-induced intestinal ischemia leads to an increase in nitrate concentration in the intestinal mucus layer, and Enterobacteriaceae, which can undergo nitrate respiration, overpopulate as a result. A systematic review published in Clinical Psychology Review summarized 26 studies, including 20 case-control studies, and found that the gut microbiota of patients with anxiety and depression exhibited an enrichment of pro-inflammatory bacteria such as Enterobacteriaceae. Thus, disorders of the gut microbiota characterized by Enterobacteriaceae are all associated with the above major brain diseases.
In summary, stroke and depression patients share common and respective unique characteristics of gut microbiota, metabolites, and immune factors. In this study, we intend to identify the key factors of intestinal bacteria and target novel biomarkers in stroke and depression through cross-sectional study of stroke and depression, using cutting-edge multi-omics technology.
- Conditions
- Acute Ischaemic Stroke, Depression
- Medical subject headings
- Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with acute ischaemic stroke | Patients who met the diagnostic criteria of the 2018 Chinese guidelines for the diagnosis and treatment of acute ischemic stroke. | |
| Depressed patients | Patients who met the depression related criteria in the Chinese classification and diagnostic criteria for mental disorders. |
What is being measured
The primary outcome is the main question the study is designed to answer.
The severity of neurological damage in stroke patients
The severity of neurological damage in stroke patient evaluated by National Institutes of Health Stroke Scale(NHISS), the scoring range is 0-42 points, with higher scores indicating more severe neurological damage.
Measured: The evaluation will be conducted on the second day after admission
The functional recovery outcomes after stroke
The functional recovery outcomes after stroke evaluated by Modified Rankin Scale(mRS), the scoring range is 0-6 points, with higher scores indicating worse functional outcome.
Measured: The evaluation will be conducted at 3 months after admission
The severity of symptoms in patients with depression
The severity of symptoms in patients with depression is evaluated by Hamilton Depression Scale(HAMD), the scoring range is 0-54 points, with higher scores indicating more severe depressive states.
Measured: The evaluation will be conducted on the second day after admission
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Apr 2024
- Study start1 Sep 2023
- Primary completion30 Jun 2024 (estimated)
- Study completion30 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Ischaemic StrokeStudies of the same condition, open and under way.
- More trials run by Zhujiang HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 320 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zhujiang Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Hongwei Zhou, Study chair, Zhujiang Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06379464
- Sponsor's protocol ID
- CALM2303
- Status last verified
- Aug 2023
- First submitted
- 6 Apr 2024
- Last updated
- 23 Apr 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Screening of New Markers of Gut Microbiota in Stroke and Depression: a Cross-sectional Study
- ClinicalTrials.gov ID
- NCT06379464
- Acronym / sponsor ID
- CALM2303
- Conditions
- Acute Ischaemic Stroke, Depression
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 320 participants (estimated)
- Lead sponsor
- Zhujiang HospitalUniversity, hospital or other
- Study start
- 1 Sep 2023 (actual)
- Primary completion
- 30 Jun 2024 (estimated)
- Study completion
- 30 Dec 2024 (estimated)
- First posted
- 23 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objectives of Study: Through the cross-sectional study of stroke and depression, key biomarkers are targeted by screening disease-associated intestinal bacteria, metabolites and immune factors through multi-omics techniques.
Detailed description
With environmental changes, population aging, and the accelerated pace of social life, cerebrovascular diseases and mental illnesses have gradually become a major disease burden in China. Stroke is the second leading cause of death globally, as well as the leading cause of death and disability in China. In recent years, the prevalence and incidence of stroke have increased significantly in our country. Global Burden of Disease 2017 reported a stroke incidence rate of 258 (95% CI, 234-284) per 100,000 person-years and a mortality rate of 88 (95% CI, 80-94) per 100,000 person-years. Depression is one of the most common psychiatric disorders, with a lifetime prevalence of 15-18%, a recurrence rate of approximately 80%, and a disease outcome that worsens with increasing age of onset. World Health Organization measurements show that the disease burden of depression accounts for 10% of the total burden of all types of illness and disability. Its pathogenesis is still unknown, treatment options are limited, and most patients suffer from recurrent or prolonged illness for life. The etiology and pathophysiological mechanisms of stroke and depression remain unknown, and objective and reliable biological diagnostic markers are lacking.
As research strategies focusing on the central nervous system have encountered difficulties, the field has begun to look to the periphery for new clues. With the advancement of multi-omics studies integrating genome, transcriptome, epigenome, proteome, and metabolomics, important roles of gut microbiota have been discovered to influence the function and structure of the nervous system by regulating metabolites, the immune system, and neurotransmitters, etc. Benakis et al. found that gut-derived IL17+γδ T cells migrate to the meninges and promote post-stroke injury. Clearance of gut microbiota induced changes in dendritic cell activity, increased Treg cells, and decreased IL17+γδ T cells, which in turn alleviated stroke injury. Therefore, T-lymphocytes dependent on intestinal immunity are strongly associated with stroke severity. Previous studies have shown that IL-17 produced by γδ T cells in the meninges is an important factor in inducing anxious behavior and IFN-γ is important in maintaining social willingness, whereas pro-inflammatory factors such as IL-1β, IL-6 and TNF-α produced by inflammatory responses are highly correlated with depression, so that T-cell immunity may be associated with depression. Stroke and depression present a similar pathogenesis and spectrum of disease traits. IL-17+γδ T cells have been shown to be involved in the mechanism of injury after ischemic stroke; high levels of IL-17 are associated with depression, which is a common comorbidity of diseases such as the above. This suggests that the relevant immune pathways represented by IL-17 and γδ T cells may be a common pathogenic mechanism for stroke and depression. Previous studies have also shown that both diseases exhibit enrichment of Enterobacteriaceae. The applicant's team's findings, published in Gut, reveal that ischemic stroke can trigger a disturbance of the gut microbiota characterized by an overproliferation of Enterobacteriaceae, and that the disturbed microbiota can further contribute to the progression of brain injury and is associated with poor stroke outcomes. The mechanism is that stroke-induced intestinal ischemia leads to an increase in nitrate concentration in the intestinal mucus layer, and Enterobacteriaceae, which can undergo nitrate respiration, overpopulate as a result. A systematic review published in Clinical Psychology Review summarized 26 studies, including 20 case-control studies, and found that the gut microbiota of patients with anxiety and depression exhibited an enrichment of pro-inflammatory bacteria such as Enterobacteriaceae. Thus, disorders of the gut microbiota characterized by Enterobacteriaceae are all associated with the above major brain diseases.
In summary, stroke and depression patients share common and respective unique characteristics of gut microbiota, metabolites, and immune factors. In this study, we intend to identify the key factors of intestinal bacteria and target novel biomarkers in stroke and depression through cross-sectional study of stroke and depression, using cutting-edge multi-omics technology.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with acute ischaemic stroke | – | –Patients who met the diagnostic criteria of the 2018 Chinese guidelines for the diagnosis and treatment of acute ischemic stroke. |
| Depressed patients | – | –Patients who met the depression related criteria in the Chinese classification and diagnostic criteria for mental disorders. |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- 1. Patients with acute ischaemic stroke; 2. Depressed patients
Key inclusion criteria (6 listed)
- Age range from 18 to 90 years old;
- Patients who met the diagnostic criteria of the 2018 Chinese guidelines for the diagnosis and treatment of acute ischemic stroke;
- Sign the informed consent form, provide relevant medical history information and provide blood, urine and stool samples.
- Age range from 18 to 90 years old;
- Patients who met the depression related criteria in the Chinese classification and diagnostic criteria for mental disorders;
Key exclusion criteria (13 listed)
- Serious systemic diseases including malignancies;
- Alanine aminotransferase or aspartate aminotransferase >2 times the upper limit of normal value or severe liver disease;
- Creatinine >1.5 times the upper limit of normal or severe nephropathy;
- A long-term history of drinking, drug taking and chemical poisoning. A long-term history of drinking refers to a history of more than 5 years, equivalent to alcohol >40g/d for men and 20g/d for women, or a history of heavy drinking within 2 weeks, equivalent to alcohol >80g/d;
- Those with previous history of intestinal tumor, irritable bowel syndrome or inflammatory bowel disease or diagnosed in Hospital;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The severity of neurological damage in stroke patients
Time frame: The evaluation will be conducted on the second day after admission
The severity of neurological damage in stroke patient evaluated by National Institutes of Health Stroke Scale(NHISS), the scoring range is 0-42 points, with higher scores indicating more severe neurological damage.
The functional recovery outcomes after stroke
Time frame: The evaluation will be conducted at 3 months after admission
The functional recovery outcomes after stroke evaluated by Modified Rankin Scale(mRS), the scoring range is 0-6 points, with higher scores indicating worse functional outcome.
The severity of symptoms in patients with depression
Time frame: The evaluation will be conducted on the second day after admission
The severity of symptoms in patients with depression is evaluated by Hamilton Depression Scale(HAMD), the scoring range is 0-54 points, with higher scores indicating more severe depressive states.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Apr 2024.
Related trials for Acute Ischaemic Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
RecruitingObservational study
Continuous Dual Aspiration Technique With Zoom System for Stroke
Ischemic Stroke, Acute Stroke
Not yet recruitingPhase 2/3
A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
Acute Ischemic Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hongwei Zhou study chair
Zhujiang Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Ischaemic Stroke and Depression, run by Zhujiang Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Kaiyu XU (13590349187, 1500810165@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The severity of neurological damage in stroke patients (time frame: The evaluation will be conducted on the second day after admission). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2024.